Influences of opioids and nanoparticles on in vitro wound healing models

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 73, Issue 1, 2009, Pages 34-42

  Wolf, Nadine B ^a   Küchler, Sarah ^a   Radowski, Michal R ^a   Blaschke, Tobias ^a   Kramer, Klaus D ^a   Weindl, Günther ^a   Kleuser, Burkhard ^a   Haag, Rainer ^a   Schäfer Korting, Monika ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Dendritic core multishell nanotransporters; HET CAM assay; Skin irritation test; Solid lipid nanoparticles; Topical opioids; Wound healing models

Indexed keywords

BUPRENORPHINE; FENTANYL CITRATE; HYDROMORPHONE; MORPHINE; NANOPARTICLE; SOLID LIPID NANOPARTICLE;

ABSORPTION; ANALGESIC ACTIVITY; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; KERATINOCYTE; SKIN IRRITATION; SLOW DRUG RELEASE; WOUND HEALING;

ANALGESICS, OPIOID; ANIMALS; CELL LINE, TRANSFORMED; CELL MOVEMENT; CELLS, CULTURED; CHICKENS; FEMALE; HUMANS; MALE; NANOPARTICLES; SKIN; SKIN IRRITANCY TESTS; WOUND HEALING;

EID: 68349141699     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2009.03.009     Document Type: Article

References (75)

1. Bigliardi-Qi M., Sumanovski L.T., Buchner S., Rufli T., and Bigliardi P.L. Mu-opiate receptor and Beta-endorphin expression in nerve endings and keratinocytes in human skin. Dermatology 209 (2004) 183-189
2. Nissen J.B., Lund M., Stengaard-Pedersen K., and Kragballe K. Enkephalin-like immunoreactivity in human skin is found selectively in a fraction of CD68-positive dermal cells: increase in enkephalin-positive cells in lesional psoriasis. Arch. Dermatol. Res. 289 (1997) 265-271
3. Stein C., Schafer M., and Hassan A.H. Peripheral opioid receptors. Ann. Med. 27 (1995) 219-221
4. Twillman R.K., Long T.D., Cathers T.A., and Mueller D.W. Treatment of painful skin ulcers with topical opioids. J. Pain Symptom Manage. 17 (1999) 288-292
5. Alvarez-Roman R., Naik A., Kalia Y.N., Guy R.H., and Fessi H. Enhancement of topical delivery from biodegradable nanoparticles. Pharm. Res. 21 (2004) 1818-1825
6. Küchler S., Radowski M.R., Blaschke T., Dathe M., Plendl J., Haag R., Schäfer-Korting M., and Kramer K.D. Nanoparticles for skin penetration enhancement - A comparison of a dendritic core-multishell-nanotransporter and solid lipid nanoparticles. Eur. J. Pharm. Biopharm. 71 (2009) 243-250
7. Santos Maia C., Mehnert W., Schaller M., Korting H.C., Gysler A., Haberland A., and Schäfer-Korting M. Drug targeting by solid lipid nanoparticles for dermal use. J. Drug Target. 10 (2002) 489-495
8. Stecova J., Mehnert W., Blaschke T., Kleuser B., Sivaramakrishnan R., Zouboulis C.C., Seltmann H., Korting H.C., Kramer K.D., and Schäfer-Korting M. Cyproterone acetate loading to lipid nanoparticles for topical acne treatment: particle characterisation and skin uptake. Pharm. Res. 24 (2007) 991-1000
9. Jenning V., Schäfer-Korting M., and Gohla S. Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties. J. Control. Release 66 (2000) 115-126
10. Mehnert W., and Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev. 47 (2001) 165-196
11. Wissing S.A., Kayser O., and Müller R.H. Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv. Rev. 56 (2004) 1257-1272
12. zur Mühlen A., Schwarz C., and Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery--drug release and release mechanism. Eur. J. Pharm. Biopharm. 45 (1998) 149-155
13. Poonawala T., Levay-Young B.K., Hebbel R.P., and Gupta K. Opioids heal ischemic wounds in the rat. Wound Repair Regen. 13 (2005) 165-174
14. Vinogradov V.A., Spevak S.E., Iarygin K.N., Korobov N.V., and Solov'eva A.I. Opioid activity of peptides and wound healing of the skin. Bull. Eksp. Biol. Med. 104 (1987) 89-91
15. Broughton II G., Janis J.E., and Attinger C.E. Wound healing: an overview. Plast. Reconstr. Surg. 117 (2006) 1e-S-32e-S
16. Jenning V., Gysler A., Schäfer-Korting M., and Gohla S.H. Vitamin A loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. Eur. J. Pharm. Biopharm. 49 (2000) 211-218
17. Lombardi Borgia S., Regehly M., Sivaramakrishnan R., Mehnert W., Korting H.C., Danker K., Röder B., Kramer K.D., and Schäfer-Korting M. Lipid nanoparticles for skin penetration enhancement-correlation to drug localization within the particle matrix as determined by fluorescence and parelectric spectroscopy. J. Control. Release 110 (2005) 151-163
18. Haag R. Supramolecular drug-delivery systems based on polymeric core-shell architectures. Angew. Chem. Int. Ed. Engl. 43 (2004) 278-282
19. Radowski M.R., Shukla A., von Berlepsch H., Böttcher C., Pickaert G., Rehage H., and Haag R. Supramolecular aggregates of dendritic multishell architectures as universal nanocarriers. Angew. Chem. Int. Ed. Engl. 46 (2007) 1265-1269
20. SCCP, The Scientific Committee on Cosmetic Products (SCCP) Opinion on safety of nanomaterials in vosmetic products, 2007. Available from: .
21. Sunder A., Kramer M., Hanselmann R., Mulhaupt R., and Frey H. Molecular nanocapsules based on amphiphilic hyperbranched polyglycerols. Angew. Chem. Int. Ed. Engl. 38 (1999) 3552-3555
22. Blaschke T., Kankate L., and Kramer K.D. Structure and dynamics of drug-carrier systems as studied by parelectric spectroscopy. Adv. Drug Deliv. Rev. 59 (2007) 403-410
23. Sivaramakrishnan R., Nakamura C., Mehnert W., Korting H.C., Kramer K.D., and Schäfer-Korting M. Glucocorticoid entrapment into lipid carriers - characterisation by parelectric spectroscopy and influence on dermal uptake. J. Control. Release 97 (2004) 493-502
24. Gysler A., Lange K., Korting H.C., and Schäfer-Korting M. Prednicarbate biotransformation in human foreskin keratinocytes and fibroblasts. Pharm. Res. 14 (1997) 793-797
25. Bartolmäs T., Heyn T., Mickeleit M., Fischer A., Reutter W., and Danker K. Glucosamine-glycerophospholipids that activate cell-matrix adhesion and migration. J. Med. Chem. 48 (2005) 6750-6755
26. Sauer B., Vogler R., Zimmermann K., Fujii M., Anzano M.B., Schäfer-Korting M., Roberts A.B., and Kleuser B. Lysophosphatidic acid interacts with transforming growth factor-beta signaling to mediate keratinocyte growth arrest and chemotaxis. J. Invest. Dermatol. 123 (2004) 840-849
27. Vogler R., Sauer B., Kim D.S., Schäfer-Korting M., and Kleuser B. Sphingosine-1-phosphate and its potentially paradoxical effects on critical parameters of cutaneous wound healing. J. Invest. Dermatol. 120 (2003) 693-700
28. Hintermann E., Bilban M., Sharabi A., and Quaranta V. Inhibitory role of alpha 6 beta 4-associated erbB-2 and phosphoinositide 3-kinase in keratinocyte haptotactic migration dependent on alpha 3 beta 1 integrin. J. Cell Biol. 153 (2001) 465-478
29. Koivisto L., Jiang G., Hakkinen L., Chan B., and Larjava H. HaCaT keratinocyte migration is dependent on epidermal growth factor receptor signaling and glycogen synthase kinase-3alpha. Exp. Cell Res. 312 (2006) 2791-2805
30. Lee P.C., Salyapongse A.N., Bragdon G.A., Shears II L.L., Watkins S.C., Edington H.D., and Billiar T.R. Impaired wound healing and angiogenesis in eNOS-deficient mice. Am. J. Physiol. 277 (1999) H1600-H1608
31. Faller C., Bracher M., Dami N., and Roguet R. Predictive ability of reconstructed human epidermis equivalents for the assessment of skin irritation of cosmetics. Toxicol. In Vitro 16 (2002) 557-572
32. Spielmann H., Hoffmann S., Liebsch M., Botham P., Fentem J.H., Eskes C., Roguet R., Cotovio J., Cole T., Worth A., Heylings J., Jones P., Robles C., Kandarova H., Gamer A., Remmele M., Curren R., Raabe H., Cockshott A., Gerner I., and Zuang V. The ECVAM international validation study on in vitro tests for acute skin irritation: report on the validity of the EPISKIN and EpiDerm assays and on the Skin Integrity Function Test. Altern. Lab. Anim. 35 (2007) 559-601
33. Spielmann H., Liebsch M., Moldenhauer F., Holzhutter H.G., Bagley D.M., Lipman J.M., Pape W.J., Miltenburger H., de Silva O., Hofer H., and Steiling W. IRAG working group 2. CAM-based assays. Interagency Regulatory Alternatives Group. Food Chem. Toxicol. 35 (1997) 39-66
34. Bigliardi-Qi M., Gaveriaux-Ruff C., Pfaltz K., Bady P., Baumann T., Rufli T., Kieffer B.L., and Bigliardi P.L. Deletion of mu- and kappa-opioid receptors in mice changes epidermal hypertrophy, density of peripheral nerve endings, and itch behavior. J. Invest. Dermatol. 127 (2007) 1479-1488
35. Bigliardi-Qi M., Gaveriaux-Ruff C., Zhou H., Hell C., Bady P., Rufli T., Kieffer B., and Bigliardi P. Deletion of delta-opioid receptor in mice alters skin differentiation and delays wound healing. Differentiation 74 (2006) 174-185
36. Salemi S., Aeschlimann A., Reisch N., Jungel A., Gay R.E., Heppner F.L., Michel B.A., Gay S., and Sprott H. Detection of kappa and delta opioid receptors in skin--outside the nervous system. Biochem. Biophys. Res. Commun. 338 (2005) 1012-1017
37. Bigliardi P.L., Buchner S., Rufli T., and Bigliardi-Qi M. Specific stimulation of migration of human keratinocytes by mu-opiate receptor agonists. J. Recept. Signal Transduct. Res. 22 (2002) 191-199
38. Bigliardi P.L., Sumanovski L.T., Buchner S., Rufli T., and Bigliardi-Qi M. Different expression of mu-opiate receptor in chronic and acute wounds and the effect of beta-endorphin on transforming growth factor beta type II receptor and cytokeratin 16 expression. J. Invest. Dermatol. 120 (2003) 145-152
39. Yuan H., Wang L.L., Du Y.Z., You J., Hu F.Q., and Zeng S. Preparation and characteristics of nanostructured lipid carriers for control-releasing progesterone by melt-emulsification. Colloids Surf. B Biointerf. 60 (2007) 174-179
40. Fang J.Y., Liu P.F., and Huang C.M. Decreasing systemic toxicity via transdermal delivery of anticancer drugs. Curr. Drug Metab. 9 (2008) 592-597
41. Liu J., Hu W., Chen H., Ni Q., Xu H., and Yang X. Isotretinoin-loaded solid lipid nanoparticles with skin targeting for topical delivery. Int. J. Pharm. 328 (2007) 191-195
42. Kuntsche J., Bunjes H., Fahr A., Pappinen S., Ronkko S., Suhonen M., and Urtti A. Interaction of lipid nanoparticles with human epidermis and an organotypic cell culture model. Int. J. Pharm. 354 (2008) 180-195
43. Schürer N., Kohne A., Schliep V., Barlag K., and Goerz G. Lipid composition and synthesis of HaCaT cells, an immortalized human keratinocyte line, in comparison with normal human adult keratinocytes. Exp. Dermatol. 2 (1993) 179-185
44. Zambruno G., Marchisio P.C., Marconi A., Vaschieri C., Melchiori A., Giannetti A., and De Luca M. Transforming growth factor-beta 1 modulates beta 1 and beta 5 integrin receptors and induces the de novo expression of the alpha v beta 6 heterodimer in normal human keratinocytes: implications for wound healing. J. Cell Biol. 129 (1995) 853-865
45. Howdieshell T.R., Webb W.L., Sathyanarayana, and McNeil P.L. Inhibition of inducible nitric oxide synthase results in reductions in wound vascular endothelial growth factor expression, granulation tissue formation, and local perfusion. Surgery 133 (2003) 528-537
46. Schwentker A., Vodovotz Y., Weller R., and Billiar T.R. Nitric oxide and wound repair: role of cytokines?. Nitric Oxide 7 (2002) 1-10
47. Noiri E., Peresleni T., Srivastava N., Weber P., Bahou W.F., Peunova N., and Goligorsky M.S. Nitric oxide is necessary for a switch from stationary to locomoting phenotype in epithelial cells. Am. J. Physiol. 270 (1996) C794-C802
48. Shimizu Y., Sakai M., Umemura Y., and Ueda H. Immunohistochemical localization of nitric oxide synthase in normal human skin: expression of endothelial-type and inducible-type nitric oxide synthase in keratinocytes. J. Dermatol. 24 (1997) 80-87
49. Yamasaki K., Edington H.D., McClosky C., Tzeng E., Lizonova A., Kovesdi I., Steed D.L., and Billiar T.R. Reversal of impaired wound repair in iNOS-deficient mice by topical adenoviral-mediated iNOS gene transfer. J. Clin. Invest. 101 (1998) 967-971
50. Herzinger T., Kleuser B., Schäfer-Korting M., and Korting H.C. Sphingosine-1-phosphate signaling and the skin. Am. J. Clin. Dermatol. 8 (2007) 329-336
51. Igarashi J., and Michel T. S1P and eNOS regulation. Biochim. Biophys. Acta 1781 (2008) 489-495
52. Tölle M., Levkau B., Keul P., Brinkmann V., Giebing G., Schonfelder G., Schafers M., von Wnuck Lipinski K., Jankowski J., Jankowski V., Chun J., Zidek W., and Van der Giet M. Immunomodulator FTY720 Induces eNOS-dependent arterial vasodilatation via the lysophospholipid receptor S1P3. Circ. Res. 96 (2005) 913-920
53. Saric A., Balog T., Sobocanec S., and Marotti T. Endomorphin 1 activates nitric oxide synthase 2 activity and downregulates nitric oxide synthase 2 mRNA expression. Neuroscience 144 (2007) 1454-1461
54. Olbrich C., and Müller R.H. Enzymatic degradation of SLN-effect of surfactant and surfactant mixtures. Int. J. Pharm. 180 (1999) 31-39
55. Iijima H., Kasai N., Chiku H., Murakami S., Sugawara F., Sakaguchi K., Yoshida H., and Mizushina Y. The inhibitory action of long-chain fatty acids on the DNA binding activity of p53. Lipids 41 (2006) 521-527
56. Cooper B., Brimer N., and Vande Pol S.B. Human papillomavirus E6 regulates the cytoskeleton dynamics of keratinocytes through targeted degradation of p53. J. Virol. 81 (2007) 12675-12679
57. Roger L., Gadea G., and Roux P. Control of cell migration: a tumour suppressor function for p53?. Biol. Cell 98 (2006) 141-152
58. Harms K., Nozell S., and Chen X. The common and distinct target genes of the p53 family transcription factors. Cell Mol. Life Sci. 61 (2004) 822-842
59. Vigano M.A., Lamartine J., Testoni B., Merico D., Alotto D., Castagnoli C., Robert A., Candi E., Melino G., Gidrol X., and Mantovani R. New p63 targets in keratinocytes identified by a genome-wide approach. EMBO J. 25 (2006) 5105-5116
60. Barbieri C.E., Tang L.J., Brown K.A., and Pietenpol J.A. Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. Cancer Res. 66 (2006) 7589-7597
61. Ichikawa T., Suenaga Y., Koda T., Ozaki T., and Nakagawara A. DeltaNp63/BMP-7-dependent expression of matrilin-2 is involved in keratinocyte migration in response to wounding. Biochem. Biophys. Res. Commun. 369 (2008) 994-1000
62. Chassaing C., Schmidt J., Eschalier A., Cardot J.M., and Dubray C. Hyperalgesia induced by cutaneous freeze injury for testing analgesics in healthy volunteers. Br. J. Clin. Pharmacol. 61 (2006) 389-397
63. Duncan R., and Izzo L. Dendrimer biocompatibility and toxicity. Adv. Drug Deliv. Rev. 57 (2005) 2215-2237
64. Stasko N.A., Johnson C.B., Schoenfisch M.H., Johnson T.A., and Holmuhamedov E.L. Cytotoxicity of polypropylenimine dendrimer conjugates on cultured endothelial cells. Biomacromolecules 8 (2007) 3853-3859
65. Hong S., Bielinska A.U., Mecke A., Keszler B., Beals J.L., Shi X., Balogh L., Orr B.G., Baker Jr. J.R., and Banaszak Holl M.M. Interaction of poly(amidoamine) dendrimers with supported lipid bilayers and cells: hole formation and the relation to transport. Bioconjug. Chem. 15 (2004) 774-782
66. Moghimi S.M., and Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res. 42 (2003) 463-478
67. Schöler N., Hahn H., Müller R.H., and Liesenfeld O. Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages. Int. J. Pharm. 231 (2002) 167-176
68. Schöler N., Olbrich C., Tabatt K., Müller R.H., Hahn H., and Liesenfeld O. Surfactant, but not the size of solid lipid nanoparticles (SLN) influences viability and cytokine production of macrophages. Int. J. Pharm. 221 (2001) 57-67
69. Weyenberg W., Filev P., Van den Plas D., Vandervoort J., De Smet K., Sollie P., and Ludwig A. Cytotoxicity of submicron emulsions and solid lipid nanoparticles for dermal application. Int. J. Pharm. 337 (2007) 291-298
70. Müller R.H., Rühl D., Runge S., Schulze-Forster K., and Mehnert W. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm. Res. 14 (1997) 458-462
71. Focher F., and Spadari S. Thymidine phosphorylase: a two-face Janus in anticancer chemotherapy. Curr. Cancer Drug Targets 1 (2001) 141-153
72. A. Richartz, Ein neues Target zur Therapie von Basaliom und spinozellulärem Karzinom - Inhibition der humanen DNA Polymerase alpha. Institut für Pharmazie, vol. Dr., Freie Universität, Berlin, 2007, p. 126.
73. Vinardell M.P., and Mitjans M. Alternative methods for eye and skin irritation tests: an overview. J. Pharm. Sci. 97 (2008) 46-59
74. Schäfer-Korting M., Bock U., Diembeck W., Düsing H.J., Gamer A., Haltner-Ukomadu E., Hoffmann C., Kaca M., Kamp H., Kersen S., Kietzmann M., Korting H.C., Krächter H.U., Lehr C.M., Liebsch M., Mehling A., Müller-Goymann C., Netzlaff F., Niedorf F., Rübbelke M.K., Schäfer U., Schmidt E., Schreiber S., Spielmann H., Vuia A., and Weimer M. The use of reconstructed human epidermis for skin absorption testing: results of the validation study. Altern. Lab. Anim. 36 (2008) 161-187
75. Eskes C., Bessou S., Bruner L., Curren R., Harbell J., Jones P., Kreiling R., Liebsch M., McNamee P., Pape W., Prinsen M.K., Seidle T., Vanparys P., Worth A., and Zuang V. Eye irritation. Altern. Lab. Anim. 33 Suppl 1 (2005) 47-81